|Mr. John F. Crowley||1.72M||N/A||50|
|Mr. Bradley L. Campbell||657.99k||N/A||41|
|Mr. William D. Baird III||543.52k||19.43k||45|
|Dr. Hung Do Ph.D.||502.32k||N/A||49|
|Dr. Jay A. Barth M.D.||782.29k||N/A||53|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.